Two sensitive reversed-phase high-performance liquid chromatographic fluorescence methods, with simple sample handling at the site of the patient, are described for the determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin (9AC). For 9AC lactone, the sample preparation was a liquid-liquid extraction with acetonitrile-nbutyl chloride (1:4, v / v), whereas the sample preparation for 9AC total (lactone plus carboxylate) was a simple deproteinization with 5% perchloric acid-methanol (1:1, v / v), which results in the conversion of the carboxylate into the lactone form. The lower limits of quantitation were 50 pg / ml and 100 pg / ml for 9AC lactone and 9AC total, respectively. The within-run precisions at four tested concentrations were #6.3% for 9AC lactone and #5.3% for 9AC total. The between-run precisions were #8.9% and #5.6%, respectively. The assays were developed to enable pharmacological analysis of 9AC in a bioavailability and oral phase I study in patients with solid tumors. © 1997 Elsevier Science B. V.
Introduction
toxicity, including diarrhea and dose-limiting myelosuppression precluded further clinical testing 20(S)-Camptothecin (CPT; NSC 94600; Fig. 1 ) is (reviewed in Ref. [3] ). After the identification of a cytotoxic plant alkaloid, that was first extracted DNA topoisomerase I as the molecular target of CPT from the wood and bark of the oriental tree Cam- [4, 5] , interest in new structure development was ptotheca acuminata, Decaisne (Nyssaceae) [1, 2] . In accelerated, with various derivatives of CPT spite of promising antitumor activity in vitro and in (semi)synthesized to enhance the aqueous solubility. animal tumor models, severe and unpredictable Two compounds of this type, viz. topotecan and irinotecan have shown impressive antitumor activity and were recently registered for clinical use in various countries, for treatment of ovarian and Fig. 1 . Chemical structures and pH-dependent interconversion of the lactone and carboxylate forms of 9AC (R5NH ) and CPT (R5H). 2 recently also introduced into clinical trials because of 2. Experimental its unprecedented antitumor activity against solid tumor xenografts [7, 8] .
2.1. Chemicals and reagents Pharmacokinetic studies of the camptothecins, including 9AC, are complicated by a chemical, pH-9AC (Lot No. 93L07A, containing the base with a dependent instability of the lactone ring ( Fig. 1 ) [9] , purity of 100%) and CPT (Lot No. 93K05A, congenerating an open-ring carboxylate, which is over taining the base with a purity of 100%) were 1000-fold less active as an inhibitor of DNA obtained from Pharmacia (New Mexico, USA). topoisomerase I [10] . The importance of this Methanol, acetonitrile (both HPLC-grade), dimethyl nonenzymatic hydrolysis reaction of the lactone sulfoxide (DMSO) and n-butyl chloride (both anamoiety in the pharmacology and toxicology of 9AC lytical grade) were purchased from Rathburn (Walkis largely unknown. To address this question, deerburn, UK). Perchloric acid (70-72%, v / v; anavelopment of analytical methodologies enabling the lytical grade) was obtained from Baker (Deventer, quantitation of both forms are required. Various Netherlands). The water was filtered and deionized authors recently described assays for the determiwith a Milli-Q-UF system (Milford, MA, USA) and nation of 9AC lactone and / or total drug levels was used in all aqueous solutions. Drug-free human (lactone plus carboxylate; 9AC total) applicable to plasma originated from healthy donors and was plasma samples obtained from patients [11] [12] [13] .
delivered by the Central Laboratory of the Blood Major drawbacks of these procedures are the necessiTransfusion Service (Amsterdam, Netherlands). ty for immediate analysis by high-performance liquid chromatography (HPLC), postcolumn acidification and / or laborious solid-phase extraction techniques.
Stock solutions and standards
We now describe novel assays for the analysis of 9AC lactone and 9AC total in human plasma, which Separate stock solutions of 9AC and CPT were only require a one-step solvent extraction for sample made by dissolving 10.0 mg of 9AC or CPT in 10.00 clean-up prior to reversed-phase HPLC with fluoresml of DMSO. A volume of 5.00 ml of these cence detection. The presented methods have been solutions was accurately transferred to 50 ml voluthoroughly validated in terms of accuracy and precimetric flasks and diluted to the mark with DMSO, sion, and are now successfully implemented in resulting in solutions containing 100 mg/ml of 9AC studies on the pharmacology of 9AC in patients with or CPT, respectively. Working solutions of 9AC solid tumors.
lactone were prepared daily at 1, 2, 10, 20, 30 and 40 ng / ml by serial dilution in a mixture of methanoladded. The sample was transferred to a low volume water-perchloric acid (500:500:1, v / v / v) from the insert of glass, and a volume of 150 ml was injected primary stock solution. Similarly, working solutions into the HPLC system. of 9AC total were made in methanol-water (1:1, v / v) at concentrations of 2, 4, 20, 100, 200 and 300 ng / ml. Spiked plasma samples used as calibrations 2.4. Sample preparation for total 9AC standards were prepared daily by addition of 50 ml of the working solutions to 950 ml of drug-free human A volume of 250 ml of 5% perchloric acidplasma, resulting in calibration standards of 50, 100, methanol (1:1, v / v) was added to 250 ml of human 500, 1000, 1500 and 2000 pg / ml for 9AC lactone plasma in a 1.5 ml polypropylene-microcentrifuge and of 100, 200, 1000, 5000, 10 000, 15 000 pg / ml tube, followed by vortex-mixing for 10 min. Subfor 9AC total.
sequently, the sample was centrifuged for 5 min at Four pools of quality control (QC) samples were 24 000 g at ambient temperature. The clear supernaprepared in human plasma in the concentrations of tant was transferred to a low volume insert of glass 250, 900, 1600 and 150 000 pg / ml for 9AC lactone and 200 ml were injected into the HPLC system. and of 500, 7500, 12 500 and 250 000 pg / ml for 9AC total. The QC samples containing the highest concentration were used as diluted control and / or for 2.5. Chromatographic system low volume injection. To minimize differences in the composition between clinical and QC samples, also
The HPLC system consisted of a constaMetric the carboxylate form of 9AC was added to the QC 3200 pump from LDC Analytical, a subsidiary of samples of 9AC lactone. The 9AC carboxylate was Thermo Instruments Systems (Riviera Beach, USA). spiked at the same concentrations as 9AC lactone
The samples were injected by a Waters 717plus and was prepared by adding 9AC in methanol-water autosampler (division of Millipore, Milford, MA, (1:1, v / v) to plasma, followed by incubation at 378C USA). A fluoriMonitor 4100 fluorescence detector for 20 h.
from LDC Analytical was used for the detection. Chromatographic separations were achieved on an Inertsil ODS-80A column (15034.6 mm I.D., 5 mm 2.3. Sample preparation for the lactone form of particle size) from GL Science (Tokyo, Japan), 9AC
protected by a Lichrospher 100 RP-18 endcapped guard column (434 mm I.D., 5 mm particle size) To 1.00 ml of human plasma a volume of 100 ml obtained from Merck (Darmstadt, Germany). of 2.5 ng / ml of CPT in methanol-water-perchloric For the assay of the lactone form of 9AC in acid (500:500:1, v/v/v) and 0.8 g of NaCl were plasma, the mobile phase was a mixture of methaadded in a glass tube supplied with PTFE-covered nol-water (40:60, v / v). The pH was adjusted to 2.20 screw cap. For the extraction, 7.5 ml of acetonitrileby addition of perchloric acid. The mobile phase for n-butyl chloride (1:4, v / v) was added and the sample the assay of 9AC total in plasma was composed of was vortex-mixed for 5 min, which resulted in the methanol-water (32.5:67.5, v / v), with the pH adformation of a gel. Subsequently, the sample was justed to 2.10 using perchloric acid. The mobile centrifuged for 2 min at 4000 g at ambient temperaphases were degassed by ultrasonication and were ture. The sample was shaken once to break the gel delivered at a flow-rate set at 1.00 ml / min for both and centrifuged for 5 min at 4000 g. The supernatant assays. The column was maintained at 408C, also for was collected in a glass tube containing 50 ml of both assays, using a model SpH99 column oven DMSO and evaporated at 508C under a gentle stream (Spark Holland, Meppel, Netherlands), and the of nitrogen, until a residue of approximately 50 ml eluents were monitored at an excitation wavelength was left over. To the residue 50 ml of methanol and of 370 nm and an emission wavelength of 450 nm, 150 ml of perchloric acid-water (1:500, v / v) was with a bandwidth of 40 nm.
Calibration
The stability of 9AC total was tested by incubation of the four QC samples at 378C for 20 h and during Acquisition and integration of chromatographic three freeze-thaw cycles. At the freeze-thaw cycles data was performed with the Chrom-Card data the QC samples were put at room temperature for 1 h analysis system (Fisons, Milan, Italy) running on an before freezing again. The stability of 9AC lactone ICW workstation. Calibration curves were made by was only tested during three quick freeze-thaw linear regression analysis of peak heights versus cycles. The samples were thawed quickly in cold 1 / concentration using the software package Lotus water and restored at 2808C within 5 to 10 min. The 2.4 (Lotus Development Corporations, New York, long term stability of 9AC total and 9AC lactone at NY, USA).
2808C was also tested at the concentrations of the QC samples over a four-month period.
Validation
The following potentially co-administered drugs were tested for interference with the analytical For the validation of the assays of 9AC lactone methods: paracetamol at a concentration of 0.50 and 9AC total in plasma, the six-points calibration mg / ml; alizapride, codeine, domperidon, morphine curves were processed in duplicate and analyzed on and ranitidine at a concentration of 0.10 mg / ml; and four occasions with the lower limit of quantitation dexamethasone and metoclopramide at concentra-(LLQ) and the QC samples in quintuplicate. For the tions of 0.05 and 0.01 mg / ml, respectively. determination of the LLQ, plasma samples of five independent individuals were taken and spiked to 2.8. Human experiments contain 50 pg / ml for 9AC lactone and 100 pg / ml for 9AC total. For the concentration accepted as the To demonstrate the applicability of the analytical LLQ, the percent deviation of at least 80% of the methods, blood samples from a patient were colsamples assayed should be #20%. The mean withinlected at 0, 20 and 40 min, and at 1, 1.5, 2, 3, 5, 7.5, run and between-run precision (expressed as the 11, 24, 28, 31, 35, 48, 52 and 55 h after oral coefficient of variation (%C. V.) for each concenadministration of 2.5 mg of 9AC. Immediately after tration, excluding the LLQ, should be #15% and sampling, the blood was centrifuged, at the site of should be #20% for the LLQ. The mean accuracy the patient, for 5 min at 3000 g at 48C. The plasma (%) for each concentration, including the LLQ, was collected and directly placed on dry-ice at should be within 85-115% of the nominal values.
2208C. Within a few hours the samples were stored The absolute recoveries were calculated on the at 2808C. basis of the concentrations of the calibration curves. For 9AC lactone the peak heights of processed plasma samples were compared with the peak 3. Results and discussion heights of two samples with a concentration equivalent to 1000 pg / ml 9AC and 250 pg / ml CPT in Calibration curves of the lactone and total (lactone plasma extracts with 100% recovery. For this purplus carboxylate forms) of 9AC in human plasma pose, 50 ml of 20 ng/ml of 9AC and 100 ml of 2.5
were linear in the range of 50 to 2000 pg / ml and 100 ng / ml of CPT in methanol-water-perchloric acid to 15 000 pg / ml, respectively. The regression corre-(500:500:1, v/v/v) were evaporated in a tube conlation coefficients were $0.992 for 9AC lactone and taining 50 ml of DMSO, and were dissolved as $0.997 for 9AC total, by using weighted (1 / conplasma extracts. For 9AC total, the peak heights of centration) linear least-squares regression analysis to processed plasma samples were compared with the prevent domination of the highest concentrations. peak heights of two samples with a concentration Intercept values of the standard curves for both 9AC equal to 5000 pg / ml of 9AC in plasma extracts with lactone and 9AC total were not significantly different 100% recovery; 25 ml of 100 ng / ml of 9AC in from zero by Student's t-test (P.0.05). The remethanol-water (1:1, v / v) was added to 975 ml tention times of 9AC and CPT in the assay of the blank plasma extract. lactone form were 7.5 and 22 min (Fig. 2) , while the retention time of 9AC in the assay of 9AC total was 12.5 min (Fig. 3) , with overall chromatographic run times of 30 and 20 min, respectively. The selectivity for the analytes is shown by the sharp resolution of the peaks and no significant interfering peaks for both assays in blank plasma samples from five independent donors. All the tested potentially coadministered drugs did not give interfering peaks for 9AC and CPT in the assay for 9AC lactone, and for 9AC in the assay for the 9AC total. The LLQ for 9AC in the assays for the lactone and total form were 50 and 100 pg / ml, respectively. The lower value of the LLQ for the determination of the lactone was a consequence of concentration of the 78.267.98% and 92.467.96%, and the recovery for 9AC in the total assay was found to be 89.666.87%. The extraction procedure was shown to be highly selective for 9-AC lactone, since less than 0.1% of the 9-AC caboxylate form present in the samples was extracted concomitantly. In both assays, extraction recoveries were independent of the spiked concentration. The within-run precisions of the LLQ samples of 9AC lactone and 9AC total were #4.2% and #10.2%, respectively. The range of accuracy for 9AC lactone was 95.6% to 112.0%. For 9AC total, the accuracy ranged from 95.2% to 107.6%. The average accuracy for QC samples at the four tested concentrations in both assays showed values ranging within 10% of the nominal values (Tables 1 and 2 ). The average within-run and between-run precisions 9AC total was found to be stable for 20 h at 378C, Table 1 The mean accuracy, the mean within-run precision and the between-run precision of the QC samples (n55) in human plasma of 9AC lactone QC and during three freeze-thaw cycles. However, 9AC re-converting the carboxylate into the corresponding lactone, enabled determination of 9AC total. The lactone was not stable during three quick freezeplasma concentration-time curves of 9AC lactone thaw cycles; there was a loss of the amount of 9AC and 9AC total forms of a patient treated orally with lactone of approximately 10% in comparison with 2.7 mg of 9AC, are given in Fig. 4 . The data indicate the mean of a set of QC samples analyzed at the that the LLQs of 50 and 100 pg / ml for 9AC lactone same time. This instability necessitates quick freezand 9AC total, respectively, are sufficient for moniing of the samples after blood sampling in order to toring drug-plasma levels in samples obtained from stabilize the ratio between 9AC lactone and 9AC patients treated at low oral doses. carboxylate. 9AC total and lactone forms were stable
In conclusion, two sensitive, selective, accurate for at least four months when stored at 2808C.
and reproducible isocratic reversed-phase HPLC Processed plasma samples were also found to be methods have been developed for the analysis of stable at ambient temperature upon standing in the 9AC lactone and 9AC total in human plasma. The autosampler tray for at least 20 h. sample pretreatment procedures are based on single Plasma collected from a patient prior to the drug solvent extractions, thereby eliminating the need of administration did not reveal the presence of interferlaborious solid-phase extraction techniques [12, 13] . ing endogenous peaks. Concentrations of 9AC lacCompared to previously described assays for 9AC, tone could be readily estimated from protein-free our new methods provide equivalent to superior extracts, whereas acidification of plasma samples, sensitivity with LLQs of 50 pg / ml for 9AC lactone and 100 pg / ml for 9AC total (lactone plus carboxylate). The methodologies described permit the analysis of patient samples, and will be implemented in future investigations on the clinical pharmacology of 9AC administered at low (oral) doses.
